Peptide-Functionalized Nanoparticles Cross Blood-Brain Barrier and Treat Schizophrenia in Mice
Nanoparticles displaying a brain-targeting peptide (KS-487) and loaded with a VIP receptor-blocking peptide (KS-133) successfully crossed the blood-brain barrier and improved cognitive dysfunction in schizophrenia model mice.
Quick Facts
What This Study Found
KS-487-displaying nanoparticles encapsulating KS-133 successfully crossed the blood-brain barrier via subcutaneous injection. Pharmacokinetic analysis confirmed time-dependent transport of KS-133 into the brain. When administered to schizophrenia model mice, the nanoparticles significantly improved cognitive dysfunction. This is the first demonstration of a multipeptide nanoparticle achieving therapeutic efficacy by inhibiting VIPR2 in the brain.
Key Numbers
Two cyclic peptides: KS-133 (VIPR2 selective antagonist) and KS-487 (LRP1 cluster IV binder).
How They Did This
Nanoparticle preparation with KS-133 encapsulated and KS-487 displayed on the surface. Click chemistry conjugation of KS-487 with ICG for brain imaging. Subcutaneous and intravenous administration in mice. Fluorescence imaging confirmed brain accumulation. Pharmacokinetic analysis of brain transport. Cognitive testing in schizophrenia mouse models.
Why This Research Matters
Getting drugs into the brain is one of medicine's biggest challenges. This study shows that peptide-functionalized nanoparticles can solve two problems at once: crossing the blood-brain barrier (using KS-487) and delivering a therapeutic peptide (KS-133) to block a schizophrenia-linked receptor. This dual-peptide approach could be applied to other brain diseases.
The Bigger Picture
This represents a convergence of two peptide technologies — cell-penetrating/targeting peptides and therapeutic peptides — into a single delivery system. If this approach works in humans, it could open new treatment avenues for schizophrenia and other neuropsychiatric disorders.
What This Study Doesn't Tell Us
Mouse study only — blood-brain barrier permeability and drug efficacy may differ in humans. Schizophrenia mouse models have limited translational value. Long-term safety of repeated dosing unknown. Only cognitive dysfunction was assessed; other schizophrenia symptoms not tested.
Questions This Raises
- ?Could this dual-peptide nanoparticle approach treat other brain diseases beyond schizophrenia?
- ?What is the long-term safety profile of repeated subcutaneous nanoparticle injections?
- ?How does the brain concentration of KS-133 via nanoparticles compare to direct injection?
Trust & Context
- Key Stat:
- First multipeptide brain therapy First study to demonstrate therapeutic efficacy of a multifunctionalized nanoparticle using two peptides to cross the blood-brain barrier and treat schizophrenia
- Evidence Grade:
- Rated preliminary: proof-of-concept mouse study. Novel technology but unvalidated in larger animals or humans.
- Study Age:
- Published in 2024. Represents cutting-edge peptide nanotechnology for brain drug delivery.
- Original Title:
- Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia.
- Published In:
- JACS Au, 4(8), 2811-2817 (2024)
- Authors:
- Sakamoto, Kotaro, Iwata, Seigo, Jin, Zihao, Chen, Lu, Miyaoka, Tatsunori, Yamada, Mei, Katahira, Kaiga, Yokoyama, Rei, Ono, Ami, Asano, Satoshi, Tanimoto, Kotaro, Ishimura, Rika, Nakagawa, Shinsaku, Hirokawa, Takatsugu, Ago, Yukio, Miyako, Eijiro
- Database ID:
- RPEP-09191
Evidence Hierarchy
Frequently Asked Questions
Can peptides cross the blood-brain barrier?
Normally peptides cannot easily cross the blood-brain barrier, but this study shows that displaying a brain-targeting peptide (KS-487) on nanoparticles enables transport across the barrier after simple subcutaneous injection.
Could peptide nanoparticles treat schizophrenia?
This mouse study provides the first proof-of-concept that a peptide-loaded nanoparticle can reach the brain and improve cognitive dysfunction in a schizophrenia model, but human testing is still needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09191APA
Sakamoto, Kotaro; Iwata, Seigo; Jin, Zihao; Chen, Lu; Miyaoka, Tatsunori; Yamada, Mei; Katahira, Kaiga; Yokoyama, Rei; Ono, Ami; Asano, Satoshi; Tanimoto, Kotaro; Ishimura, Rika; Nakagawa, Shinsaku; Hirokawa, Takatsugu; Ago, Yukio; Miyako, Eijiro. (2024). Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia.. JACS Au, 4(8), 2811-2817. https://doi.org/10.1021/jacsau.4c00311
MLA
Sakamoto, Kotaro, et al. "Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia.." JACS Au, 2024. https://doi.org/10.1021/jacsau.4c00311
RethinkPeptides
RethinkPeptides Research Database. "Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanopa..." RPEP-09191. Retrieved from https://rethinkpeptides.com/research/sakamoto-2024-cyclic-peptides-ks133-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.